Fourth Quarter & Full Year 2025 Results
Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community on January 29, 2026. The presentation was followed by a Q&A session.
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
2025 marked another strong year of profitable growth for Sanofi as we delivered multiple regulatory approvals, advanced our pipeline with several positive Phase 3 readouts, and achieved three successful launches across medicines and vaccines. This momentum reflects our evolution as an R&D-driven, AI-powered biopharma company harnessing the power of science to deliver breakthroughs for patients.
Paul Hudson
Chief Executive Officer